Show simple item record

dc.contributor.authorSmyth, Een_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-16T10:48:02Z
dc.date.issued2017-12en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29103869en_US
dc.identifierS1470-2045(17)30719-2en_US
dc.identifier.citationLancet Oncol, 2017, 18 (12), pp. 1561 - 1563en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1187
dc.identifier.eissn1474-5488en_US
dc.identifier.doi10.1016/S1470-2045(17)30719-2en_US
dc.format.extent1561 - 1563en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectHumansen_US
dc.subjectPaclitaxelen_US
dc.subjectPhthalazinesen_US
dc.subjectPiperazinesen_US
dc.subjectStomach Neoplasmsen_US
dc.titleMissing a GOLDen opportunity in gastric cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-09-06en_US
rioxxterms.versionofrecord10.1016/S1470-2045(17)30719-2en_US
rioxxterms.licenseref.startdate2017-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfLancet Oncolen_US
pubs.issue12en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume18en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorSmyth, Lizzyen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record